198835-05-1

Basic information

• Product Name: (1r,4s,6s)-rel-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate
• Synonyms: (1r,4s,6s)-rel-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate;Racemic-(1S,4R,6R)-Tert-Butyl 6-Hydroxy-2-Azabicyclo[2.2.1]Heptane-2-Carboxylate
• CAS NO: 198835-05-1
• Molecular Formula: C11H19NO3
• Molecular Weight: 213.27346
• Mol File: 198835-05-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 310.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.181±0.06 g/cm3(Predicted)
• PKA: 14.72±0.20(Predicted)
• CAS DataBase Reference: (1r,4s,6s)-rel-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1r,4s,6s)-rel-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate(198835-05-1)
• EPA Substance Registry System: (1r,4s,6s)-rel-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate(198835-05-1)

Safety Data

• Hazardous Substances Data: 198835-05-1(Hazardous Substances Data)

Usage

General Description

The chemical compound "(1r,4s,6s)-rel-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate" is a derivative of the bicyclic compound azabicyclo[2.2.1]heptane. It contains a hydroxyl group at the sixth position and a tert-butyl group attached to the carboxylate at the second position. (1r,4s,6s)-rel-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate has a specific stereochemistry, denoted by the (1r,4s,6s) configuration, indicating the positions of substituents around the bicyclic structure. It is commonly used in organic synthesis and pharmaceutical research as a building block for the preparation of various biologically active molecules.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1099570-25-8 tert-butyl (1RS,4SR,6RS)-6-hydroxy-2-azabicyclo[2.2.1] heptane-2-carboxylate 
• 1932285-09-0 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 542-92-7 cyclopenta-1,3-diene 
• 149494-50-8 (-)-(1S,1'R)-2-(1'-Phenylethyl)-2-azabicyclo<2.2.1>hept-5-ene 
• 702666-72-6 tert-butyl (1S,4R)-2-azabicyclo[2.2.1]heptan-5-en-2-carboxylate 
• 130931-83-8 (1S,4R)-2-azabicyclo[2,2,1]hept-5-en-3-one 
• 1932285-09-0 (1S,4R)-tert-butyl 6-oxo-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 198835-01-7 (1S,4R,6S)-tert-butyl 6-hydroxy-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 188345-71-3 2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]hept-5-ene 

Downstream Products

• 1932285-09-0 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1932285-09-0 (1S,4R)-tert-butyl 6-oxo-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 1005077-74-6 (1S,4S,6R)-tert-butyl 6-amino-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 1005077-74-6 endo-6-amino-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1005077-74-6 exo-6-amino-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1932285-09-0 tert-butyl 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate 

Relevant articles and documents

Nitrogen-containing heterocyclic amino derivative, preparation method thereof and anti-HIV-1 medicine

The invention provides a nitrogen-containing heterocyclic ring amino derivative, a preparation method thereof and an anti-HIV-1 medicine, and belongs to the technical field of medicine application. The nitrogen-containing heterocyclic ring amino derivative provided by the invention can interfere with the process of hydrolyzing Gap and Gap-Pol precursor polyprotein by HIV-1 protease, and has high HIV-1 protease inhibitory activity; meanwhile, the nitrogen-containing heterocyclic ring amino derivative provided by the invention has remarkable inhibitory activity on wild type anti-HIV-1 medicine strains and high anti-DRV-medicine strains, has low cytotoxicity, and has a good application prospect as an anti-AIDS medicine.

Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist

A class of novel pyrimidine derivatives bearing diverse conformationally restricted azabicyclic ether/amine were designed, synthesized and evaluated for their GPR119 agonist activities against type 2 diabetes. Most compounds exhibited superior hEC50

Synthesis of novel azanorbornylpurine derivatives

Azanorbornylpurine derivatives were prepared by Mitsunobu reaction of appropriate hydroxyazanorbornane derivative with 6-chloropurine or construction of purine base at azanorbornylamines. The prepared target compounds were evaluated for antiviral activity and effect on neuronal and muscle nicotinic acetylcholine receptors.